Latest Headlines
-
Light-Activated Drugs Against Neuropathic Pain
7/12/2024
A team of researchers led by the Institute for Bioengineering of Catalonia (IBEC) has developed light-activated derivatives of the anti-epileptic drug carbamazepine to treat neuropathic pain.
-
A Comprehensive Derivative Synthesis Method For Development Of New Antimicrobial Drugs
7/12/2024
A method to screen a wide variety of drug candidates without laborious purification steps could advance the fight against drug-resistant bacteria.
-
ADM Korea Announces Niclosamide-Based Metabolic Anticancer Drug's First Clinical Trial Target As 'Prostate Cancer Patients Resistant To Hormone Therapy'
7/11/2024
ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be 'prostate cancer patients resistant to hormone therapy.'
-
Ipsen And Foreseen Biotechnology Announce Exclusive Global Licensing Agreement For Antibody-Drug Conjugate With First-In-Class Potential
7/11/2024
Ipsen and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation and metastasis.
-
Evotec And Pfizer Collaborate To Advance Drug Discovery In France
7/10/2024
Evotec SE today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer.
-
Exscientia Launches AWS AI-Powered Platform To Advance Drug Discovery
7/10/2024
Exscientia plc today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI) and machine learning (ML) services to power its platform for end-to-end drug discovery and automation.
-
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio With Launch Of CHO Express Antibodies
7/10/2024
Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies.
-
Researchers Awarded Close To $18M Grant To Develop New AI Platform To AID Disease Study And Drug Development
7/9/2024
A team of local scientists has been awarded a grant close to SGD$18M to develop a new data platform called TISHUMAP1 that will offer researchers and clinicians a cellular, location-based approach for disease biomarker analysis to empower and accelerate drug discovery efforts in Singapore and Asia.
-
Abata Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Clinical Evaluation Of ABA-101 In Progressive Multiple Sclerosis
7/9/2024
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate the first-in-human (FIH) Phase 1 study of ABA-101 in patients with progressive multiple sclerosis (MS).
-
Obsidian Therapeutics Announces FDA Fast Track Designation For OBX-115 For The Treatment Of Advanced Melanoma
7/9/2024
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), for the treatment of patients with metastatic or locally advanced melanoma that is refractory to or has relapsed after PD-1/PD-L1–based immune checkpoint inhibitors (ICI).